Qingxin Mu

Director of Preclinical Science

Dr. Qingxin Mu brings over 15 years of research experience in pharmaceutical sciences, nanomedicine, and drug delivery, with deep expertise in translational cancer research. He previously held faculty and research positions at the University of Washington, the University of Kansas, and St. Jude Children’s Research Hospital. Dr. Mu has authored more than 60 peer-reviewed publications, is an inventor on multiple patents, and actively contributes to the scientific community through grant review work for the NIH, NSF, and international funding agencies. He also serves as a reviewer for approximately 80 scientific journals and sits on the editorial boards of several, including Journal of Pharmaceutical Sciences, Frontiers in Oncology, and International Journal of Molecular Sciences. As principal investigator, he has led several intra- and extramural research projects, including an NCI-funded R21 grant.

At BrYet, he leads the design and execution of preclinical programs supporting the company’s research and development efforts based on its innovative nanoporous silicon microparticle and transport oncophysics platform. His current work focuses on advancing novel therapeutics from formulation through in vitro and in vivo validation, with the goal of enabling clinical translation.